Attached files

file filename
10-Q - 10-Q - PLIANT THERAPEUTICS, INC.plrx-10q_20200930.htm
EX-31.2 - EX-31.2 - PLIANT THERAPEUTICS, INC.plrx-ex312_8.htm
EX-31.1 - EX-31.1 - PLIANT THERAPEUTICS, INC.plrx-ex311_6.htm
EX-10.1 - EX-10.1 - PLIANT THERAPEUTICS, INC.plrx-ex101_224.htm

 

Exhibit 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Bernard Coulie, Chief Executive Officer of Pliant Therapeutics, Inc. (the “Company”), and Keith Cummings, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1.

The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2020, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 10, 2020

 

/s/  Bernard Coulie

Bernard Coulie, M.D., Ph.D.

President and Chief Executive Officer

(Principal Executive Officer)

 

/s/  Keith Cummings

Keith Cummings, M.D., MBA

Chief Financial Officer

(Principal Financial Officer)

 

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.